IL112195A - D.N.A. A two-stranded encoder encoding RNA that forms a triangular helix with a designated single-stranded nucleic acid and pharmaceutical preparations containing it - Google Patents

D.N.A. A two-stranded encoder encoding RNA that forms a triangular helix with a designated single-stranded nucleic acid and pharmaceutical preparations containing it

Info

Publication number
IL112195A
IL112195A IL11219594A IL11219594A IL112195A IL 112195 A IL112195 A IL 112195A IL 11219594 A IL11219594 A IL 11219594A IL 11219594 A IL11219594 A IL 11219594A IL 112195 A IL112195 A IL 112195A
Authority
IL
Israel
Prior art keywords
double
region
helix
stranded dna
forming
Prior art date
Application number
IL11219594A
Other languages
English (en)
Hebrew (he)
Other versions
IL112195A0 (en
Original Assignee
Centre Nat Rech Scient
Inst Nat Sante Rech Med
Museum Nat D Histoire Naturell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Inst Nat Sante Rech Med, Museum Nat D Histoire Naturell filed Critical Centre Nat Rech Scient
Publication of IL112195A0 publication Critical patent/IL112195A0/xx
Publication of IL112195A publication Critical patent/IL112195A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/152—Nucleic acids forming more than 2 strands, e.g. TFOs on a single-stranded target, e.g. fold-back TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL11219594A 1993-12-29 1994-12-29 D.N.A. A two-stranded encoder encoding RNA that forms a triangular helix with a designated single-stranded nucleic acid and pharmaceutical preparations containing it IL112195A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9315798A FR2714383B1 (fr) 1993-12-29 1993-12-29 Contrôle de l'expression de gènes.

Publications (2)

Publication Number Publication Date
IL112195A0 IL112195A0 (en) 1995-03-15
IL112195A true IL112195A (en) 2004-08-31

Family

ID=9454520

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11219594A IL112195A (en) 1993-12-29 1994-12-29 D.N.A. A two-stranded encoder encoding RNA that forms a triangular helix with a designated single-stranded nucleic acid and pharmaceutical preparations containing it

Country Status (16)

Country Link
US (1) US6133024A (ja)
EP (2) EP0737248B1 (ja)
JP (1) JPH09507387A (ja)
AT (1) ATE378405T1 (ja)
AU (1) AU1388495A (ja)
CA (1) CA2180032C (ja)
DE (1) DE69435043T2 (ja)
DK (1) DK0737248T3 (ja)
ES (1) ES2297830T3 (ja)
FI (1) FI120740B (ja)
FR (1) FR2714383B1 (ja)
IL (1) IL112195A (ja)
NO (1) NO962707L (ja)
PT (1) PT737248E (ja)
WO (1) WO1995018223A1 (ja)
ZA (1) ZA9410367B (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
NZ547283A (en) 1998-03-20 2008-06-30 Commw Scient Ind Res Org Control of gene expression
US6525185B1 (en) 1998-05-07 2003-02-25 Affymetrix, Inc. Polymorphisms associated with hypertension
JPH11335269A (ja) 1998-05-19 1999-12-07 Hisamitsu Pharmaceut Co Inc 遺伝子関連医薬の経口投与固形製剤
EP1147204A1 (en) * 1999-01-28 2001-10-24 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
WO2000063364A2 (en) * 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
EP1229134A3 (en) * 2001-01-31 2004-01-28 Nucleonics, Inc Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
FR2822476B1 (fr) 2001-03-23 2004-04-02 Aventis Pharma Sa Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice
US20050075298A1 (en) * 2002-01-31 2005-04-07 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa
US20040043003A1 (en) * 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
EP1572902B1 (en) 2002-02-01 2014-06-11 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US20040014956A1 (en) 2002-02-01 2004-01-22 Sequitur, Inc. Double-stranded oligonucleotides
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
DE202005004135U1 (de) * 2005-03-11 2005-05-19 Klocke Verpackungs-Service Gmbh Mehrkomponentenverpackung mit Applikator
CA2825894C (en) 2011-02-02 2021-11-30 Amgen Inc. Prognosis of cancer using a circulating biomarker
AU2012335541B2 (en) 2011-11-11 2017-07-06 Duke University Combination drug therapy for the treatment of solid tumors
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399676A (en) * 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
FR2675803B1 (fr) * 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
WO1993012230A1 (en) * 1991-12-13 1993-06-24 Sri International Triple-helix formation at (punpyn).(punpyn) tracts
FR2687411A1 (fr) * 1992-02-13 1993-08-20 Nice Sophia Antipolis Universi Vecteur comportant un gene viral transcrit par l'arn polymerase iii, et procede de production intracellulaire d'arn.
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5700657A (en) * 1993-12-13 1997-12-23 Genzyme Corporation Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby

Also Published As

Publication number Publication date
JPH09507387A (ja) 1997-07-29
FI962693A (fi) 1996-06-28
FI962693A0 (fi) 1996-06-28
US6133024A (en) 2000-10-17
FR2714383B1 (fr) 1996-02-09
NO962707D0 (no) 1996-06-26
EP0737248A1 (fr) 1996-10-16
EP0737248B1 (fr) 2007-11-14
DK0737248T3 (da) 2008-03-25
ZA9410367B (en) 1995-09-20
DE69435043T2 (de) 2008-09-04
ES2297830T3 (es) 2008-05-01
AU1388495A (en) 1995-07-17
NO962707L (no) 1996-06-26
FR2714383A1 (fr) 1995-06-30
EP1939290A3 (fr) 2011-07-06
CA2180032A1 (fr) 1995-07-06
PT737248E (pt) 2008-02-25
WO1995018223A1 (fr) 1995-07-06
EP1939290A2 (fr) 2008-07-02
IL112195A0 (en) 1995-03-15
CA2180032C (fr) 2010-08-10
DE69435043D1 (de) 2007-12-27
FI120740B (fi) 2010-02-15
ATE378405T1 (de) 2007-11-15

Similar Documents

Publication Publication Date Title
US6133024A (en) Gene expression control
AU2020217347A1 (en) COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION
US20180201921A1 (en) CRISPRs
EP1931806B1 (en) Pkr activation via hybridization chain reaction
US20130245096A1 (en) COMPOSITIONS AND METHODS FOR ACTIVATING EXPRESSION BY A SPECIFIC ENDOGENOUS miRNA
CN107073051A (zh) 重组aav变体及其用途
JPH08509500A (ja) 抗ウイルス性グアノシンリッチオリゴヌクレオチド
US12031135B2 (en) p63 inactivation for the treatment of heart failure
KR20020067959A (ko) 단방향성 안티센스 ｃＤＮＡ 라이브러리 구축을 통한 신규대규모 유전자 검색 및 기능 분석 시스템
WO2020055941A1 (en) Compositions and methods for excision with single grna
WO2007058323A1 (ja) 核酸ホモポリマー結合機能性核酸医薬品の製造法
US20230304014A1 (en) Mirna-485 inhibitor for huntington's disease
JPH09176038A (ja) 抗炎症性アンチセンス薬物
US20190071673A1 (en) CRISPRs WITH IMPROVED SPECIFICITY
CN114908089B (zh) 3’utr的构建方法和应用
JP5777240B2 (ja) 新規オリゴヌクレオチド誘導体及びそれから成るＮＦ−κＢデコイ
AU2003236659B2 (en) Cooperative oligonucleotides
CN1256149C (zh) rhTPO昆虫杆状病毒基因治疗载体及其生产方法和应用
Frauendorf et al. Interaction of linear and folded modified antisense oligonucleotides with sequences containing secondary structure elements
JP3728463B2 (ja) 新規マキシザイム
WO2023212687A1 (en) Systems for enhancing mrna expression and uses thereof
Saygılı et al. Spinal muscular atrophy and current new generation treatment
WO2005032561A1 (ja) ＨＩＶ−Ｖｐｒの機能に関する発明
WO2020118218A1 (en) Short dna aptamers and methods for promoting remyelination
Stankov Antisense antiviral agents: about the optimal approach

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired